The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review.
immune checkpoint inhibitors
melanoma
oncology
rechallenge
retreatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Jul 2023
04 Jul 2023
Historique:
received:
30
04
2023
revised:
24
06
2023
accepted:
02
07
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Despite a great success of immunotherapy in cancer treatment, a great number of patients will become resistant. This review summarizes recent reports on immune checkpoint inhibitor retreatment or rechallenge in order to overcome primary resistance. The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The search was performed using PubMed, Web of Science and Scopus. In total, 31 articles were included with a total of 812 patients. There were 16 retreatment studies and 13 rechallenge studies. We identified 15 studies in which at least one parameter (overall response rate or disease control rate) improved or was stable at secondary treatment. Interval treatment, primary response to and the cause of cessation for the first immune checkpoint inhibitors seem to be promising predictors of secondary response. However, high heterogeneity of investigated cohorts and lack of reporting guidelines are limiting factors for current in-depth analysis.
Identifiants
pubmed: 37444600
pii: cancers15133490
doi: 10.3390/cancers15133490
pmc: PMC10340255
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2021 May;22(5):643-654
pubmed: 33857412
Br J Cancer. 2014 Apr 2;110(7):1721-6
pubmed: 24619072
Clin Cancer Res. 2020 Nov 15;26(22):5869-5878
pubmed: 32816891
Eur J Cancer. 2021 Aug;153:213-222
pubmed: 34214936
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97
pubmed: 32368178
Lancet Respir Med. 2021 May;9(5):467-475
pubmed: 33096027
Immunotherapy. 2021 Feb;13(3):189-194
pubmed: 33225795
JAMA Oncol. 2019 Sep 01;5(9):1310-1317
pubmed: 31169866
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Future Oncol. 2020 Jul;16(20):1441-1453
pubmed: 32410465
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Clin Lung Cancer. 2020 Sep;21(5):e497-e510
pubmed: 32605892
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
Nat Rev Cancer. 2012 Mar 22;12(4):237-51
pubmed: 22437869
Clin Lung Cancer. 2020 Mar;21(2):e45-e48
pubmed: 31902695
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32532839
Eur J Cancer. 2020 Oct;138:68-76
pubmed: 32861208
Anticancer Res. 2019 Jul;39(7):3917-3921
pubmed: 31262921
J Cancer Res Clin Oncol. 2022 Nov;148(11):3081-3089
pubmed: 34982222
Nat Commun. 2016 Oct 31;7:13354
pubmed: 27796306
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Cancer Chemother Pharmacol. 2017 Nov;80(5):999-1004
pubmed: 28983657
Semin Oncol. 2017 Apr;44(2):136-140
pubmed: 28923212
Br J Cancer. 2016 May 10;114(10):1084-9
pubmed: 27124339
Breast Cancer Res Treat. 2022 Feb;192(1):1-17
pubmed: 35015209
Cancers (Basel). 2018 Jan 25;10(2):
pubmed: 29370105
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32169873
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35217575
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Eur J Cancer. 2018 Sep;101:160-164
pubmed: 30071444
Clin Genitourin Cancer. 2023 Apr;21(2):286-294
pubmed: 36481176
BMC Health Serv Res. 2014 Nov 21;14:579
pubmed: 25413154
Cancer Chemother Pharmacol. 2019 Oct;84(4):873-880
pubmed: 31444618
Clin Cancer Res. 2013 Apr 15;19(8):2232-9
pubmed: 23444228
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e893-e897
pubmed: 35778267
NAR Cancer. 2020 Feb 17;2(1):zcaa002
pubmed: 34316682
Cancer Chemother Pharmacol. 2018 Jun;81(6):1105-1109
pubmed: 29675747
Melanoma Res. 2016 Apr;26(2):153-6
pubmed: 26636908
Biomed Pharmacother. 2020 Apr;124:109821
pubmed: 31962285
J Clin Med. 2019 Dec 31;9(1):
pubmed: 31906082
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32066646
Future Oncol. 2016 Dec;12(23):2683-2688
pubmed: 27581765
Melanoma Res. 2017 Aug;27(4):321-325
pubmed: 28257394
Curr Treat Options Oncol. 2022 Sep;23(9):1153-1168
pubmed: 35876957
Cancers (Basel). 2021 Jun 07;13(11):
pubmed: 34200219
J Dermatol. 2020 Aug;47(8):907-910
pubmed: 32515012
Front Oncol. 2022 Feb 07;12:809304
pubmed: 35198442
J Immunother. 2021 Jul-Aug 01;44(6):224-233
pubmed: 33734142
Biomedicines. 2022 Sep 28;10(10):
pubmed: 36289687
Signal Transduct Target Ther. 2022 Jul 29;7(1):258
pubmed: 35906199
Crit Rev Oncol Hematol. 2022 Feb;170:103579
pubmed: 35007699
J Immunother Cancer. 2017 Aug 15;5(1):66
pubmed: 28807048
Jpn J Clin Oncol. 2019 Aug 1;49(8):762-765
pubmed: 31090906
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Oncotarget. 2018 Aug 17;9(64):32298-32304
pubmed: 30190787
Acta Otolaryngol. 2022 Feb;142(2):206-212
pubmed: 35148228
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Nat Commun. 2021 Aug 6;12(1):4755
pubmed: 34362890
JAMA Oncol. 2020 Oct 1;6(10):1606-1610
pubmed: 32469396
Ann Oncol. 2019 Jul 1;30(7):1154-1161
pubmed: 30923820